Real-world Secukinumab Outcomes in Canadian HS Patients
Key facts
- Where
- Calgary, Cobourg, Fredericton, Hamilton, London, Markham, Mississauga, Richmond Hill, Saint-Jérôme, Saskatoon, Sherbrooke, St. John's, Toronto, and Winnipeg, CanadaSee the 14 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07282015, who can take part
Where in Canada
- Calgary, AlbertaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Cobourg, OntarioHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Fredericton, New BrunswickHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Hamilton, OntarioHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- London, OntarioHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Markham, OntarioHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Mississauga, OntarioHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Richmond Hill, OntarioHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Saint-Jérôme, QuebecHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Saskatoon, SaskatchewanHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Sherbrooke, QuebecHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- St. John's, Newfoundland and LabradorHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Toronto, OntarioHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Winnipeg, ManitobaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07282015
- Record updated
- 23 June 2026
- Original description
The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.Read full original descriptionShow less
A Prospective Study to Describe the Real-world Treatment Outcomes in Canadian Patients With Moderate-to-severe Hidradenitis Suppurativa Treated With secukInumab (HS-RISE)
The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.
Inclusion: Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed; Adult patients at the time of informed consent signature; Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist; Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit; Patients who can understand written and spoken Canadian English or French.
Exclusion: Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM; Patients who have had any prior exposure to secukinumab (i.e., >7 days prior to the baseline visit); Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.